Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis

Kiyonori Kuwahara, Shigeo Oba, Shunsuke Nakae, Natsuki Hattori, Eriel Sandika Pareira, Seiji Yamada, Hikaru Sasaki, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose

Research output: Contribution to journalArticle

Abstract

The genetic features of isocitrate dehydrogenase-wild-type (IDH-wt) lower-grade gliomas (LGGs; World Health Organization grades II and III) are not well defined. This study analyzed the genetic and other features of IDH-wt LGGs to develop a subclassification that can be used to predict their prognosis. Clinical, histopathological, and genetic features of 35 cases of diffuse IDH-wt astrocytoma and IDH-wt anaplastic astrocytoma were analyzed. The following genetic factors were examined: mutations of B-rapidly accelerated fibrosarcoma, telomerase reverse transcriptase promoter (TERTp), histone 3 family 3A, and alpha-thalassemia/mental retardation syndrome, X-linked; and copy number aberrations. In the univariate analysis, the following factors were associated with poor overall survival (OS): the histopathological diagnosis, TERTp mutation, the gain of chromosome 7 (+ 7), and the loss of chromosome 10q (− 10q). In the multivariate analysis, + 7, − 10q, and TERTp mutation were independent prognostic factors associated with poor OS. The median OS was significantly worse for patients who harbored at least one of these factors than for those without any of them (18.5 vs. 54.5 months, P = 0.002). The subclassification of IDH-wt LGGs according to the genetic factors + 7, − 10q, and TERTp mutation is potentially useful for predicting the prognosis.

Original languageEnglish
Pages (from-to)135-143
Number of pages9
JournalBrain Tumor Pathology
Volume36
Issue number4
DOIs
Publication statusPublished - 01-10-2019

Fingerprint

Isocitrate Dehydrogenase
Glioma
Telomerase
Mutation
Chromosomes, Human, Pair 7
Astrocytoma
Survival
Fibrosarcoma
Histones
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Kuwahara, Kiyonori ; Oba, Shigeo ; Nakae, Shunsuke ; Hattori, Natsuki ; Pareira, Eriel Sandika ; Yamada, Seiji ; Sasaki, Hikaru ; Abe, Masato ; Hasegawa, Mitsuhiro ; Hirose, Yuichi. / Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis. In: Brain Tumor Pathology. 2019 ; Vol. 36, No. 4. pp. 135-143.
@article{9c7da31ba6344bfa9d96bfb625cdab70,
title = "Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis",
abstract = "The genetic features of isocitrate dehydrogenase-wild-type (IDH-wt) lower-grade gliomas (LGGs; World Health Organization grades II and III) are not well defined. This study analyzed the genetic and other features of IDH-wt LGGs to develop a subclassification that can be used to predict their prognosis. Clinical, histopathological, and genetic features of 35 cases of diffuse IDH-wt astrocytoma and IDH-wt anaplastic astrocytoma were analyzed. The following genetic factors were examined: mutations of B-rapidly accelerated fibrosarcoma, telomerase reverse transcriptase promoter (TERTp), histone 3 family 3A, and alpha-thalassemia/mental retardation syndrome, X-linked; and copy number aberrations. In the univariate analysis, the following factors were associated with poor overall survival (OS): the histopathological diagnosis, TERTp mutation, the gain of chromosome 7 (+ 7), and the loss of chromosome 10q (− 10q). In the multivariate analysis, + 7, − 10q, and TERTp mutation were independent prognostic factors associated with poor OS. The median OS was significantly worse for patients who harbored at least one of these factors than for those without any of them (18.5 vs. 54.5 months, P = 0.002). The subclassification of IDH-wt LGGs according to the genetic factors + 7, − 10q, and TERTp mutation is potentially useful for predicting the prognosis.",
author = "Kiyonori Kuwahara and Shigeo Oba and Shunsuke Nakae and Natsuki Hattori and Pareira, {Eriel Sandika} and Seiji Yamada and Hikaru Sasaki and Masato Abe and Mitsuhiro Hasegawa and Yuichi Hirose",
year = "2019",
month = "10",
day = "1",
doi = "10.1007/s10014-019-00348-9",
language = "English",
volume = "36",
pages = "135--143",
journal = "Brain Tumor Pathology",
issn = "1433-7398",
publisher = "Springer Japan",
number = "4",

}

Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis. / Kuwahara, Kiyonori; Oba, Shigeo; Nakae, Shunsuke; Hattori, Natsuki; Pareira, Eriel Sandika; Yamada, Seiji; Sasaki, Hikaru; Abe, Masato; Hasegawa, Mitsuhiro; Hirose, Yuichi.

In: Brain Tumor Pathology, Vol. 36, No. 4, 01.10.2019, p. 135-143.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II–III gliomas to establish genetic predictors of poor prognosis

AU - Kuwahara, Kiyonori

AU - Oba, Shigeo

AU - Nakae, Shunsuke

AU - Hattori, Natsuki

AU - Pareira, Eriel Sandika

AU - Yamada, Seiji

AU - Sasaki, Hikaru

AU - Abe, Masato

AU - Hasegawa, Mitsuhiro

AU - Hirose, Yuichi

PY - 2019/10/1

Y1 - 2019/10/1

N2 - The genetic features of isocitrate dehydrogenase-wild-type (IDH-wt) lower-grade gliomas (LGGs; World Health Organization grades II and III) are not well defined. This study analyzed the genetic and other features of IDH-wt LGGs to develop a subclassification that can be used to predict their prognosis. Clinical, histopathological, and genetic features of 35 cases of diffuse IDH-wt astrocytoma and IDH-wt anaplastic astrocytoma were analyzed. The following genetic factors were examined: mutations of B-rapidly accelerated fibrosarcoma, telomerase reverse transcriptase promoter (TERTp), histone 3 family 3A, and alpha-thalassemia/mental retardation syndrome, X-linked; and copy number aberrations. In the univariate analysis, the following factors were associated with poor overall survival (OS): the histopathological diagnosis, TERTp mutation, the gain of chromosome 7 (+ 7), and the loss of chromosome 10q (− 10q). In the multivariate analysis, + 7, − 10q, and TERTp mutation were independent prognostic factors associated with poor OS. The median OS was significantly worse for patients who harbored at least one of these factors than for those without any of them (18.5 vs. 54.5 months, P = 0.002). The subclassification of IDH-wt LGGs according to the genetic factors + 7, − 10q, and TERTp mutation is potentially useful for predicting the prognosis.

AB - The genetic features of isocitrate dehydrogenase-wild-type (IDH-wt) lower-grade gliomas (LGGs; World Health Organization grades II and III) are not well defined. This study analyzed the genetic and other features of IDH-wt LGGs to develop a subclassification that can be used to predict their prognosis. Clinical, histopathological, and genetic features of 35 cases of diffuse IDH-wt astrocytoma and IDH-wt anaplastic astrocytoma were analyzed. The following genetic factors were examined: mutations of B-rapidly accelerated fibrosarcoma, telomerase reverse transcriptase promoter (TERTp), histone 3 family 3A, and alpha-thalassemia/mental retardation syndrome, X-linked; and copy number aberrations. In the univariate analysis, the following factors were associated with poor overall survival (OS): the histopathological diagnosis, TERTp mutation, the gain of chromosome 7 (+ 7), and the loss of chromosome 10q (− 10q). In the multivariate analysis, + 7, − 10q, and TERTp mutation were independent prognostic factors associated with poor OS. The median OS was significantly worse for patients who harbored at least one of these factors than for those without any of them (18.5 vs. 54.5 months, P = 0.002). The subclassification of IDH-wt LGGs according to the genetic factors + 7, − 10q, and TERTp mutation is potentially useful for predicting the prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85069477458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069477458&partnerID=8YFLogxK

U2 - 10.1007/s10014-019-00348-9

DO - 10.1007/s10014-019-00348-9

M3 - Article

VL - 36

SP - 135

EP - 143

JO - Brain Tumor Pathology

JF - Brain Tumor Pathology

SN - 1433-7398

IS - 4

ER -